JPRN-UMIN000015203尚未招募未知
Effect of dapagliflozin on blood pressure, cardiac function, visceral fat in type 2 diabetes mellitus patients with hypertension. - Effect of dapagliflozin on blood pressure, cardiac function, visceral fat in type 2 diabetes mellitus patients with hypertension.
Takeda Hospital Medical Examination Center0 个研究点目标入组 30 人开始时间: 2014年9月18日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients who are Type I or Secondary diabetic mellitus 2) Patients who are treating with Insulin theraphy at the time of study initiation 3) Patients who are severe infectious disease, perioperative, and severe trauma 4)Patients who are pregnant, lactating, and possibly pregnant women and those planning to become pregnant 5)Patients with myocardial infarction, angina pectoris, cerebral stroke, or cerebral infarction before 3 month 6) patients with Arrhythmia,atrial fibrillation 7) Patients with a history of hypersensitivity to investigational drugs 8) Patients with cancer 9) Patients who receive steroid therapy with inflammatory affection 10) Patients whom doctor judges as ineligible to this study
研究者
相似试验
已完成
3 期
DECLARE-TIMI58JPRN-jRCT2080222423AstraZeneca KK17,150
进行中（未招募）
1 期
This study is being carried out to evaluate the effect of a drug called dapagliflozin when added to current treatment for type 2 diabetes on cardiovascular events.EUCTR2013-000239-28-NLAstraZeneca AB17,150
进行中（未招募）
1 期
This study is being carried out to evaluate the effect of a drug called dapagliflozin when added to current treatment for type 2 diabetes on cardiovascular events.Type 2 Diabetes mellitusMedDRA version: 19.1Level: SOCClassification code 10027433Term: Metabolism and nutrition disordersSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 19.1Level: LLTClassification code 10012613Term: Diabetes mellitus non-insulin-dependentSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2013-000239-28-SEAstraZeneca AB17,160
进行中（未招募）
1 期
This study is being carried out to evaluate the effect of a drug called dapagliflozin when added to current treatment for type 2 diabetes on cardiovascular events.Type 2 Diabetes mellitusMedDRA version: 19.1Level: LLTClassification code 10012613Term: Diabetes mellitus non-insulin-dependentSystem Organ Class: 100000004861EUCTR2013-000239-28-SKAstraZeneca AB17,150
进行中（未招募）
1 期
This study is being carried out to evaluate the effect of a drug called dapagliflozin when added to current treatment for type 2 diabetes on cardiovascular events.Type 2 Diabetes mellitusMedDRA version: 20.0 Level: LLT Classification code 10012613 Term: Diabetes mellitus non-insulin-dependent System Organ Class: 100000072461EUCTR2013-000239-28-CZAstraZeneca AB17,160